Peer-reviewed veterinary case report
Deracoxib treatment shrinks bladder cancer tumors in 26 dogs
By McMillan, Sarah K et al.·Published in Journal of the American Veterinary Medical Association·2011·Department of Veterinary Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder.
- Species:
- dog
Plain-English summary
A group of 26 dogs with transitional cell carcinoma (TCC) of the urinary bladder were treated with a medication called deracoxib to see if it could help shrink their tumors. After treatment, 4 dogs showed some improvement, while 17 had stable disease, meaning their tumors didn't get worse. The dogs were monitored for side effects, and while most tolerated the medication well, a few experienced mild issues like stomach problems. On average, the dogs lived about 323 days after starting treatment, which suggests that deracoxib can be a helpful option for managing TCC in dogs.
People also search for: dog bladder cancer treatment · transitional cell carcinoma in dogs · deracoxib side effects in dogs
Abstract
OBJECTIVE-To evaluate the antitumor activity and toxic effects of deracoxib, a selective cyclooxygenase-2 inhibitor, in dogs with transitional cell carcinoma (TCC) of the urinary bladder. DESIGN-Clinical trial. Animals-26 client-owned dogs with naturally occurring, histologically confirmed, measurableTCC of the urinary bladder. PROCEDURES-Dogs were treated PO with deracoxib at a dosage of 3 mg/kg/d (1.36 mg/lb/d) as a single-agent treatment for TCC. Tumor response was assessed via radiography, abdominal ultrasonography, and ultrasonographic mapping of urinary bladder masses. Toxic effects of deracoxib administration in dogs were assessed through clinical observations and hematologic and biochemical analyses. RESULTS-Of 24 dogs for which tumor response was assessed, 4 (17%) had partial remission, 17 (71%) had stable disease, and 3 (13%) had progressive disease; initial response could not be assessed in 2 of 26 dogs. The median survival time was 323 days. Median time to progressive disease was 133 days. Renal, hepatic, and gastrointestinal abnormalities attributed to deracoxib administration were noted in 4% (1/26), 4% (1/26), and 19% (5/26) of dogs, respectively. CONCLUSIONS AND CLINICAL RELEVANCE-Results indicated that deracoxib was generally well tolerated by dogs and had antitumor activity against TCC.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21985349/